

RESEARCH REPORT



LIQUID BIOPSY MARKETS
BY CANCER, USAGE, BIOMARKER, PLACE, & PRODUCT
WITH PRICE AND VOLUME OUTLOOK.
INCLUDING EXECUTIVE AND CONSULTANT GUIDES AND
CUSTOMIZED FORECASTING AND ANALYSIS
2023 - 2027





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1	Market Guides	26
1.1	Liquid Biopsy Market - Strategic Situation Analysis	27
1.2	Guide for Executives, Marketing, Sales, and Business Development Staff.....	29
1.3	Guide for Management Consultants and Investment Advisors.....	31
2	Introduction and Market Definition	32
2.1	What is Liquid Biopsy?.....	33
2.2	The Sequencing Revolution	34
2.3	Market Definition	36
2.3.1	Revenue Market Size.....	36
2.4	Methodology.....	38
2.4.1	Methodology.....	38
2.4.2	Sources.....	38
2.4.3	Authors	38
2.5	Perspective: Healthcare and the IVD Industry	40
2.5.1	Global Healthcare Spending	40
2.5.2	Spending on Diagnostics.....	42
2.5.3	Important Role of Insurance for Diagnostics	43
3	Market Overview.....	44
3.1	Players in a Dynamic Market.....	45

3.1.1 Academic Research Lab	46
3.1.2 Diagnostic Test Developer.....	47
3.1.3 Instrumentation Supplier	47
3.1.4 Chemical/Reagent Supplier.....	47
3.1.5 Pathology Supplier	48
3.1.6 Independent Clinical Laboratory	48
3.1.7 Public National/regional Laboratory	48
3.1.8 Hospital Laboratory	49
3.1.9 Physicians Office Lab (POLS)	49
3.1.10 Audit Body	50
3.1.11 Certification Body.....	50
3.2 Using Biopsies.....	52
3.2.1 Cancer.....	52
3.2.2 Precancerous conditions.....	53
3.2.3 Inflammatory conditions.....	53
3.3 Biopsy Sites.....	54
3.4 The Situation Today – Biopsy Analysis	56
3.5 Evidence of Cancer - Liquid Biopsy Technology.....	57
3.5.1 The Big Picture on Liquid Biopsy Technology	57
3.5.2 The Role of CTCs.....	60
3.5.3 Application of CTCs	61
3.5.4 CellSearch Detection- Ultimate Sensitivity	62
3.5.5 Epic Sciences Detection- Imaging Takes the Lead.....	63
3.5.6 Maintrac Detection – The Microscope.....	64

3.5.7 Other Methods	66
3.5.8 ctDNA Role	67
3.5.9 ctDNA Applications.....	68
3.5.10 Exosomes and Micro Vesicles – New Kid on the Block.....	70
3.5.11 The Multiple Play.....	73
3.6 Cancer Treatment Protocol Under Siege.....	75
3.6.1 Issues to Liquid Biopsy Adoption – Double Diagnostics	76
3.6.2 The Cancer Screening Market Opportunity.....	77
3.6.2.1 GRAIL – What Is It?	78
3.6.3 Cancer Management vs. Diagnosis	79
3.6.3.1 The Role of Risk Assessment	79
3.6.3.2 Managing Therapy.....	80
3.6.3.3 Monitoring Disease – What Is It?	80
3.6.4 Phases of Adoption – Looking into The Future	81
3.6.5 The Promise of Liquid Biopsy	82
3.7 Structure of Industry Plays a Part.....	84
3.7.1 Hospital Testing Share	84
3.7.2 Economies of Scale.....	84
3.7.2.1 Hospital vs. Central Lab.....	85
3.7.3 Physician Office Lab's.....	86
3.7.4 Physician's and POCT	86
4 Market Trends	88
4.1 Factors Driving Growth	89
4.1.1 Non-Invasive Game Changer.....	89

4.1.2	Lower Cost	90
4.1.3	Greater Accuracy	90
4.1.4	Wide Range of Potential Uses	90
4.1.5	Aging Population.....	91
4.2	Factors Limiting Growth	94
4.2.1	Lower prices.....	94
4.2.2	Lack of Standards	95
4.2.3	Protocol Resistance.....	95
4.2.4	Initial Adoption Cost.....	95
4.2.5	Conclusion	95
4.3	Instrumentation and Automation	96
4.3.1	Instruments Key to Market Share.....	96
4.3.2	Bioinformatics Plays a Role	96
4.4	Diagnostic Technology Development	97
4.4.1	Next Generation Sequencing Fuels a Revolution.....	98
4.4.2	Impact of NGS on pricing	99
4.4.3	Pharmacogenomics Blurs Diagnosis and Treatment.....	99
4.4.4	CGES Testing, A Brave New World	100
4.4.5	Biochips/Giant magneto resistance based assay.....	100
5	Liquid Biopsy Recent Developments	102
5.1	Recent Developments – Importance and How to Use This Section	103
5.1.1	Importance of These Developments	103
5.1.2	How to Use This Section.....	103
5.2	Liquid Biopsy Shortens Time to Treatment	103

5.3	Guardant Health MRD Test Garners Coverage.....	104
5.4	IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership.....	104
5.5	FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic	105
5.6	Epic Sciences Raises \$24M for Breast Cancer Liquid Biopsy Test	106
5.7	GenoMe Diagnostics Preparing DPCR-Based Ovarian Cancer Test	107
5.8	Sophia Genetics to Commercialize Liquid Biopsy Test.....	110
5.9	Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx	111
5.10	Liquid Biopsy Startup Haystack Oncology Raises \$56M	112
5.11	Hedera Dx to Launch Liquid Biopsy Streamlined Platform	113
5.12	PamGene Expanding Liquid Biopsy Assays.....	115
5.13	Liquid Biopsy Firm Hedera Dx Raises €14M	118
5.14	MDxHealth Plans One-Stop Shop for Prostate Cancer Dx.....	118
5.15	Precision Oncology Dx Access Varies Widely in Europe	121
5.16	Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic.....	125
5.17	Predicine Receives CE Mark for Blood and Urine Liquid Biopsy	128
5.18	BillionToOne Launches First Liquid Biopsy Products	129
5.19	Dxcover Advances Multicancer Detection Platform.....	129
5.20	CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test .	132
5.21	Illumina Sues Guardant Health Over Patents.....	132
5.22	Invitae to Expand Cancer Testing Portfolio.....	135
5.23	Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies	139
5.24	IVBH Bio Takes Aim at With Liquid Biopsy Incubator.....	140
5.25	Molecular Health, Eone-Diagnostics Ink Liquid Biopsy Partnership	143
5.26	Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech	143

5.27	BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy	146
5.28	EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform.....	149
5.29	Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding.....	152
5.30	Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition.....	153
5.31	Bio-Techne to Acquire Asuragen for up to \$320M	157
5.32	Personalis Broadens Liquid Biopsy Offering	158
5.33	Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition.....	160
5.34	Delfi Diagnostics Plans Multi-Cancer Screening Test.....	163
5.35	Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response.....	164
5.36	Liquid Biopsy NGS Panels - Diverse Test Claims.....	167
5.37	CMS Colon Cancer Screening Memo Bodes Well for Assays.....	173
5.38	Natera Liquid Biopsy Test Coverage to Expand	175
5.39	Freenome Closes Financing to Support Early Cancer Detection Trial.....	176
5.40	C\$2.6M Liquid Biopsy Initiative	177
5.41	NeoGenomics, Invata Partner for Lung Cancer Liquid Biopsy	178
5.42	Liquid Biopsy Shows Promise as Screen for Cancers	179
5.43	Invata launches RaDaR™ for the detection of residual disease and recurrence...	180
5.44	Liquid Biopsy Assay Detects 50+ Types of Cancer.....	181
5.45	Liquid Biopsy Study Confirms Concordance with Tissue Biopsy.....	183
6	Profiles of Key Players.....	186
6.1	Abbott Laboratories.....	187
6.2	AccuraGen Inc.	189
6.3	Acuamark Diagnostics	190

6.4	Admera Health, LLC.....	191
6.5	Agilent/Dako	193
6.6	Amoy Diagnostics Co., Ltd.....	196
6.7	Anchor Dx.....	197
6.8	ANGLE plc.....	199
6.9	Applied DNA Sciences	200
6.10	ARUP Laboratories.....	202
6.11	AVIVA Systems Biology.....	204
6.12	Baylor Miraca Genetics Laboratories	205
6.13	Beckman Coulter Diagnostics.....	206
6.14	Becton, Dickinson and Company	208
6.15	BGI Genomics Co. Ltd	210
6.16	Bioarray Genetics.....	212
6.17	Biocartis	213
6.18	Biocept, Inc.....	215
6.19	Biodesix Inc.	217
6.20	BioFluidica.....	218
6.21	bioMérieux Diagnostics.....	219
6.22	Bioneer Corporation	222
6.23	Bio-Rad Laboratories, Inc.....	224
6.24	Bio-Techne	227
6.25	Bioview	229
6.26	Bolidics	231
6.27	Boreal Genomics.....	233

6.28	Burning Rock.....	234
6.29	Cardiff Oncology	236
6.30	Caris Molecular Diagnostics	237
6.31	CellCarta	238
6.32	CellMax Life	240
6.33	Cepheid (Danaher)	241
6.34	Circulogene.....	243
6.35	Cizzle Biotech	244
6.36	Clinical Genomics	245
6.37	Cytolumina Technologies Corp.	246
6.38	Datar Cancer Genetics Limited.....	247
6.39	Diagnologix LLC.....	248
6.40	Dxcover.....	249
6.41	Enzo Biochem	250
6.42	Epic Sciences.....	252
6.43	Epigenomics AG.....	253
6.44	Eurofins Scientific	254
6.45	Exact Sciences	257
6.46	Fluxion Biosciences.....	259
6.47	Freenome.....	260
6.48	Fyr Diagnostics	261
6.49	GeneFirst Ltd.....	263
6.50	Genetron Holdings	264
6.51	GILUPI Nanomedizin.....	266

6.52	Guardant Health	267
6.53	HansaBiomed	268
6.54	Haystack Oncology	269
6.55	HeiScreen.....	270
6.56	Helomics.....	272
6.57	iCellate.....	274
6.58	ICON PLC	275
6.59	Illumina	277
6.60	Incell Dx.....	279
6.61	Inivata	280
6.62	INOVIQ	281
6.63	Integrated Diagnostics	282
6.64	Invitae Corporation.....	283
6.65	Janssen Diagnostics	284
6.66	Lunglife AI Inc	285
6.67	MDNA Life SCIENCES, Inc.....	286
6.68	MDx Health	287
6.69	Menarini Silicon Biosystems.....	289
6.70	Mesa Laboratories, Inc.	290
6.71	Millipore Sigma	292
6.72	Miltenyi Biotec	293
6.73	miR Scientific.....	294
6.74	Myriad Genetics/Myriad RBM	295
6.75	NantHealth, Inc.	297

6.76	Natera	299
6.77	NeoGenomics	301
6.78	Novogene Bioinformatics Technology Co., Ltd.....	303
6.79	On-Chip Biotechnologies	305
6.80	Oncocyte.....	307
6.81	OncoDNA	308
6.82	Oxford Nanopore Technologies	309
6.83	PamGene	311
6.84	Panagene.....	312
6.85	Perkin Elmer.....	313
6.86	Personal Genome Diagnostics.....	315
6.87	Precision Medicine Group	316
6.88	PrecisionMed	317
6.89	Predicine	318
6.90	Promega	319
6.91	Qiagen	321
6.92	Rarecells SAS.....	324
6.93	RareCyte	325
6.94	Roche Molecular Diagnostics	326
6.95	Screencell	328
6.96	Siemens Healthineers	329
6.97	simfo GmbH.....	331
6.98	Singlera Genomics Inc.....	332
6.99	Standard BioTools	333

6.100 Sysmex Inostics.....	335
6.101 Tempus Labs, Inc.....	337
6.102 Thermo Fisher Scientific Inc.....	338
6.103 Todos Medical	341
6.104 Veracyte	342
6.105 Volition	343
6.106 Vortex Biosciences	344
7 The Global Market for Liquid Biopsy Diagnostics.....	345
7.1 Global Market Overview by Country	346
7.1.1 Table – Global Market by Country.....	346
7.1.2 Chart - Global Market by Country.....	347
7.2 Global Market by Cancer - Overview.....	348
7.2.1 Table – Global Market by Cancer	348
7.2.2 Chart – Global Market by Cancer – Base/Final Year Comparison	349
7.2.3 Chart – Global Market by Cancer – Base Year	350
7.2.4 Chart – Global Market by Cancer – End Year.....	351
7.2.5 Chart – Global Market by Cancer – Share by Year	352
7.2.6 Chart – Global Market by Cancer – Segments Growth.....	353
7.3 Global Market by Usage - Overview.....	354
7.3.1 Table – Global Market by Usage.....	354
7.3.2 Chart – Global Market by Usage – Base/Final Year Comparison	355
7.3.3 Chart – Global Market by Usage – Base Year.....	356
7.3.4 Chart – Global Market by Usage – End Year	357
7.3.5 Chart – Global Market by Usage – Share by Year.....	358

7.3.6	Chart – Global Market by Usage – Segments Growth	359
7.4	Global Market by Place - Overview	360
7.4.1	Table – Global Market by Place.....	360
7.4.2	Chart – Global Market by Place – Base/Final Year Comparison	361
7.4.3	Chart – Global Market by Place – Base Year.....	362
7.4.4	Chart – Global Market by Place – End Year	363
7.4.5	Chart – Global Market by Place – Share by Year.....	364
7.4.6	Chart – Global Market by Place – Segments Growth	365
7.5	Global Market by Marker - Overview	366
7.5.1	Table – Global Market by Marker	366
7.5.2	Chart – Global Market by Marker – Base/Final Year Comparison	367
7.5.3	Chart – Global Market by Marker – Base Year	368
7.5.4	Chart – Global Market by Marker – End Year	369
7.5.5	Chart – Global Market by Marker – Share by Year.....	370
7.5.6	Chart – Global Market by Marker – Segments Growth	371
7.6	Global Market by Product - Overview	372
7.6.1	Table – Global Market by Product.....	372
7.6.2	Chart – Global Market by Product – Base/Final Year Comparison	373
7.6.3	Chart – Global Market by Product – Base Year.....	374
7.6.4	Chart – Global Market by Product – End Year	375
7.6.5	Chart – Global Market by Product – Share by Year.....	376
7.6.6	Chart – Global Market by Product – Segments Growth	377
8	Global Liquid Biopsy Diagnostic Markets – By Cancer.....	378
8.1	Breast	379

8.1.1	Table Breast – by Country	379
8.1.2	Table Breast – by Country, Price.....	380
8.1.3	Table Breast – by Country Volume.....	381
8.1.4	Chart - Breast Growth	382
8.2	Colorectal.....	383
8.2.1	Table Colorectal – by Country	383
8.2.2	Table Colorectal – by Country, Price.....	384
8.2.3	Table Colorectal – by Country, Volume.....	385
8.2.4	Chart - Colorectal Growth.....	386
8.3	Cervical.....	387
8.3.1	Table Cervical – by Country	387
8.3.2	Table Cervical – by Country, Price.....	388
8.3.3	Table Cervical – by Country, Volume	389
8.3.4	Chart - Cervical Growth	390
8.4	Lung.....	390
8.4.1	Table Lung – by Country	391
8.4.2	Table Lung – by Country, Price.....	392
8.4.3	Table Lung – by Country, Volume	393
8.4.4	Chart - Lung Growth	394
8.5	Prostate	395
8.5.1	Table Prostate – by Country	395
8.5.2	Table Prostate – by Country, Price	396
8.5.3	Table Prostate – by Country, Volume	397
8.5.4	Chart – Prostate Growth	398

8.6 Other	399
8.6.1 Table Other – by Country	399
8.6.2 Table Other – by Country, Price	400
8.6.3 Table Other – by Country, Volume	401
8.6.4 Chart - Other Growth.....	402
9 Global Liquid Biopsy Diagnostic Markets – by Usage.....	403
9.1 Screening.....	404
9.1.1 Table Screening – by Country	404
9.2 Chart - Screening Growth	405
9.3 Diagnostic.....	406
9.3.1 Table Diagnostic – by Country	406
9.3.2 Chart - Diagnostic Growth.....	407
9.4 Therapy	408
9.4.1 Table Therapy – by Country.....	408
9.4.2 Chart - Therapy Growth.....	409
9.5 Monitor.....	410
9.5.1 Table Monitor – by Country	410
9.5.2 Chart - Monitor Growth.....	411
10 Global Liquid Biopsy Diagnostic Markets – by Place	412
10.1 Hospital Lab	413
10.1.1 Table Hospital Lab – by Country	413
10.1.2 Chart - Hospital Lab Growth.....	414
10.2 Lab Service	415
10.2.1 Table Lab Service – by Country	415

10.2.2 Chart - Lab Service Growth.....	416
10.3 Lab Outpatient.....	417
10.3.1 Table Lab Outpatient – by Country	417
10.3.2 Chart - Lab Outpatient Growth	418
10.4 Other Lab.....	419
10.4.1 Table Other Lab – by Country	419
10.4.2 Chart - Other Lab Growth	420
11 Global Liquid Biopsy Diagnostic Markets – by Marker	421
11.1 Circulating Tumor Cell.....	422
11.1.1 Table Circulating Tumor Cell – by Country	422
11.1.2 Chart - Circulating Tumor Cell Growth	423
11.2 Cell Free DNA	424
11.2.1 Table Cell Free DNA – by Country.....	424
11.2.2 Chart - Cell Free DNA Growth	425
11.3 Vesicle.....	426
11.3.1 Table Vesicle – by Country	426
11.3.2 Chart - Vesicle Growth.....	427
11.4 Other Marker	428
11.4.1 Table Other Marker – by Country.....	428
11.4.2 Chart - Other Marker Growth	429
12 Global Liquid Biopsy Diagnostic Markets – by Product.....	430
12.1 Kits.....	431
12.1.1 Table Kits – by Country	431
12.1.2 Chart - Kits Growth	432

12.2 Instruments.....	433
12.2.1 Table Instruments – by Country	433
12.2.2 Chart - Instruments Growth.....	434
12.3 Service.....	435
12.3.1 Table Service – by Country	435
12.3.2 Chart - Service Growth	436
13 Appendices.....	437
13.1 United States Medicare System: Clinical Laboratory Fees Schedule	437

Table of Tables

Table 1 Market Players by Type	46
Table 2 Biopsy Sites	54
Table 3 LB Clinical Applications by Entity	75
Table 4 Advantages of Liquid Biopsy in Screening Market	78
Table 5 Outlook - Phases of Liquid Biopsy Adoption by Year.....	81
Table 6 Five Factors Driving Growth.....	89
Table 7 Factors Limiting Growth	94
Table 8 Key Diagnostic Laboratory Technology Trends	97
Table 9 Next Generation Sequencing Technologies – Speed and Cost	98
Table 10 - Global Market by Region	346
Table 11 Global Market by Cancer	348
Table 12 Global Market by Usage.....	354
Table 13 Global Market by Place.....	360
Table 14 Global Market by Marker.....	366
Table 15 Global Market by Product.....	372
Table 16 Breast by Country	379
Table 17 Breast by Country Price.....	380
Table 18 Breast by Country Volume.....	381
Table 19 Colorectal by Country	383
Table 20 Colorectal by Country Price	384
Table 21 Colorectal by Country Volume	385

Table 22 Cervical by Country	387
Table 23 Cervical by Country Price.....	388
Table 24 Cervical by Country Volume.....	389
Table 25 Lung by Country	391
Table 26 Lung by Country Price.....	392
Table 27 Lung by Country Volume	393
Table 28 Prostate by Country	395
Table 29 Prostate by Country Price	396
Table 30 Prostate by Country Volume	397
Table 31 Other by Country.....	399
Table 32 Other by Country Price	400
Table 33 Other by Country Volume	401
Table 34 Screening by Country	404
Table 35 Diagnostic by Country	406
Table 36 Therapy by Country.....	408
Table 37 Monitor by Country	410
Table 38 Hospital Lab by Country	413
Table 39 Lab Service by Country.....	415
Table 40 Lab Outpatient by Country	417
Table 41 Other Lab by Country	419
Table 42 Circulating Tumor Cell by Country	422
Table 43 Cell Free DNA by Country.....	424
Table 44 Vesicle by Country	426
Table 45 Other Marker by Country.....	428

Table 46 Kits by Country	431
Table 47 Instruments by Country	433
Table 48 Service by Country	435
Table 49 Clinical Lab Fee Schedule	437

Table of Figures

Figure 1 Global Healthcare Spending Picture	41
Figure 2 The Global Lab Test Pie.....	42
Figure 3 The Road to Diagnostics	45
Figure 4 Comparison of Liquid vs Tissue Biopsy.....	57
Figure 5 Entities Analyzed in liquid Biopsy	59
Figure 6 Characteristics of Different Vesicle Types	73
Figure 7 The Changing Age of World Population	92
Figure 8 Health Care Consumption by Age	93
Figure 9 Cancer Incidence - Age at Diagnosis.....	93
Figure 10 Global Market Regional Share Chart	347
Figure 11 Global Market by Cancer - Base vs. Final	349
Figure 12 Global Market by Cancer Base Year	350
Figure 13 Global Market by Cancer End Year	351
Figure 14 Cancer Share by Year	352
Figure 15 Cancer Segments Growth.....	353
Figure 16 Global Market by Usage - Base vs. Final.....	355
Figure 17 Global Market by Usage Base Year.....	356
Figure 18 Global Market by Usage End Year	357
Figure 19 Usage Share by Year.....	358
Figure 20 Usage Segments Growth	359
Figure 21 Global Market by Place - Base vs. Final.....	361

Figure 22 Global Market by Place Base Year.....	362
Figure 23 Global Market by Place End Year	363
Figure 24 Place Share by Year.....	364
Figure 25 Place Segments Growth	365
Figure 26 Global Market by Marker - Base vs. Final	367
Figure 27 Global Market by Marker Base Year.....	368
Figure 28 Global Market by Marker End Year	369
Figure 29 Marker Share by Year.....	370
Figure 30 Marker Segments Growth.....	371
Figure 31 Global Market by Product - Base vs. Final.....	373
Figure 32 Global Market by Product Base Year.....	374
Figure 33 Global Market by Product End Year.....	375
Figure 34 Product Share by Year.....	376
Figure 35 Product Segments Growth	377
Figure 36 Breast Growth	382
Figure 37 Colorectal Diagnostics Growth.....	386
Figure 38 Cervical Growth	390
Figure 39 Lung Growth	394
Figure 40 Prostate Growth.....	398
Figure 41 Other Growth.....	402
Figure 42 Screening Growth	405
Figure 43 Diagnostic Growth	407
Figure 44 Therapy Growth.....	409
Figure 45 Monitor Growth.....	411

Figure 46 Hospital Lab Growth.....	414
Figure 47 Lab Service Growth.....	416
Figure 48 Lab Outpatient Growth	418
Figure 49 Other Lab Growth	420
Figure 50 Circulating Tumor Cell Growth	423
Figure 51 Cell Free DNA Growth.....	425
Figure 52 Vesicle Growth	427
Figure 53 Other Marker Growth.....	429
Figure 54 Kits Growth	432
Figure 55 Instruments Growth	434
Figure 56 Service Growth	436